Food Noise, Intrusive Thoughts, and Depression - Improvement on Tirzepatide: A Case Report

CASE REPORT
Amirah Alhowiti

 

For citation: Alhowiti A. Food Noise, Intrusive Thoughts, and Depression - Improvement on Tirzepatide: A Case Report. International Journal of Biomedicine. 2026;16(3):406-409. doi:10.21103/Article16(3)_CR5

Originally published September 5, 2026

Abstract: 

Tirzepatide (Mounjaro) is a dual long-acting glucose-dependent insulinotropic polypeptide receptor and glucagon-like peptide-1 receptor agonist. Tirzepatide was approved for the treatment of type 2 diabetes in the USA, Europe, and Asia. In addition, tirzepatide showed a substantial sustained weight loss and retarded the progression to type 2 diabetes. However, concerns about its association with depression, suicidality, and various compulsive disorders, including compulsive shopping, were raised. Food noise is common among patients with hyperactive autistic spectrum disorder, which is a common disorder affecting 1/100 of children worldwide. We reported a case of depression, intrusive thoughts, and food noise improvement following tirzepatide in a 34-year-old Saudi female. Tirzepatide (Mounjaro) could be repurposed for the treatment of intrusive thoughts and food noise in patients with high body mass index.

Keywords: 
tirzepatide • type 2 diabetes • body mass index • food noise
References: 
  1. FDA-Approved Drugs to Treat Overweight and Obesity. J Psychosoc Nurs Ment Health Serv. 2022 Aug;60(8):7-8. doi: 10.3928/02793695-20220615-79. Epub 2022 Aug 1. PMID: 35917244.
  2. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021 Apr;46:101102. doi: 10.1016/j.molmet.2020.101102. Epub 2020 Oct 14. PMID: 33068776; PMCID: PMC8085572.
  3. Graaf Cd, Donnelly D, Wootten D, Lau J, Sexton PM, Miller LJ, Ahn JM, Liao J, Fletcher MM, Yang D, Brown AJ, Zhou C, Deng J, Wang MW. Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes. Pharmacol Rev. 2016 Oct;68(4):954-1013. doi: 10.1124/pr.115.011395. PMID: 27630114; PMCID: PMC5050443.
  4. Zhao X, Wang M, Wen Z, Lu Z, Cui L, Fu C, Xue H, Liu Y, Zhang Y. GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. Front Endocrinol (Lausanne). 2021 Aug 23;12:721135. doi: 10.3389/fendo.2021.721135. PMID: 34497589; PMCID: PMC8419463.
  5. Ma X, Liu Z, Ilyas I, Little PJ, Kamato D, Sahebka A, Chen Z, Luo S, Zheng X, Weng J, Xu S. GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential. Int J Biol Sci. 2021 May 11;17(8):2050-2068. doi: 10.7150/ijbs.59965. PMID: 34131405; PMCID: PMC8193264.
  6. McIntyre RS, Mansur RB, Rosenblat JD, Kwan ATH. The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS). Expert Opin Drug Saf. 2024 Jan;23(1):47-55. doi: 10.1080/14740338.2023.2295397. Epub 2023 Dec 19. PMID: 38087976.
  7. Tobaiqy M, Elkout H. Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database. Int J Clin Pharm. 2024 Apr;46(2):488-495. doi: 10.1007/s11096-023-01694-7. Epub 2024 Jan 24. PMID: 38265519; PMCID: PMC10960895.
  8. Chen X, Zhao P, Wang W, Guo L, Pan Q. The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis. Am J Geriatr Psychiatry. 2024 Jan;32(1):117-127. doi: 10.1016/j.jagp.2023.08.010. Epub 2023 Aug 21. PMID: 37684186.
  9. Cooper DH, Ramachandra R, Ceban F, Di Vincenzo JD, Rhee TG, Mansur RB, Teopiz KM, Gill H, Ho R, Cao B, Lui LMW, Jawad MY, Arsenault J, Le GH, Ramachandra D, Guo Z, McIntyre RS. Glucagon-like peptide 1 (GLP-1) receptor agonists as a protective factor for incident depression in patients with diabetes mellitus: A systematic review. J Psychiatr Res. 2023 Aug;164:80-89. doi: 10.1016/j.jpsychires.2023.05.041. Epub 2023 Jun 5. PMID: 37331261.
  10. Hayashi D, Edwards C, Emond JA, Gilbert-Diamond D, Butt M, Rigby A, Masterson TD. What Is Food Noise? A Conceptual Model of Food Cue Reactivity. Nutrients. 2023 Nov 17;15(22):4809. doi: 10.3390/nu15224809. PMID: 38004203; PMCID: PMC10674813.
  11. Zeidan J, Fombonne E, Scorah J, Ibrahim A, Durkin MS, Saxena S, Yusuf A, Shih A, Elsabbagh M. Global prevalence of autism: A systematic review update. Autism Res. 2022 May;15(5):778-790. doi: 10.1002/aur.2696. Epub 2022 Mar 3. PMID: 35238171; PMCID: PMC9310578.
  12. Arillotta D, Floresta G, Papanti Pelletier GD, Guirguis A, Corkery JM, Martinotti G, Schifano F. Exploring the Potential Impact of GLP-1 Receptor Agonists on Substance Use, Compulsive Behavior, and Libido: Insights from Social Media Using a Mixed-Methods Approach. Brain Sci. 2024 Jun 20;14(6):617. doi: 10.3390/brainsci14060617. PMID: 38928616; PMCID: PMC11202225.
  13. Järvinen A, Laine MK, Tikkanen R, Castrén ML. Beneficial Effects of GLP-1 Agonist in a Male With Compulsive Food-Related Behavior Associated With Autism. Front Psychiatry. 2019 Mar 1;10:97. doi: 10.3389/fpsyt.2019.00097. PMID: 30881319; PMCID: PMC6405420.
  14. Andersen A, Lund A, Knop FK, Vilsbøll T. Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol. 2018 Jul;14(7):390-403. doi: 10.1038/s41574-018-0016-2. PMID: 29728598.
  15. Vallöf D, Maccioni P, Colombo G, Mandrapa M, Jörnulf JW, Egecioglu E, Engel JA, Jerlhag E. The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents. Addict Biol. 2016 Mar;21(2):422-37. doi: 10.1111/adb.12295. Epub 2015 Aug 25. PMID: 26303264; PMCID: PMC5049632.
  16. Fuccillo MV. Striatal Circuits as a Common Node for Autism Pathophysiology. Front Neurosci. 2016 Feb 9;10:27. doi: 10.3389/fnins.2016.00027. PMID: 26903795; PMCID: PMC4746330.
  17. Cork SC, Richards JE, Holt MK, Gribble FM, Reimann F, Trapp S. Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain. Mol Metab. 2015 Aug 5;4(10):718-31. doi: 10.1016/j.molmet.2015.07.008. PMID: 26500843; PMCID: PMC4588458.
  18. Manoharan SVRR, Madan R. GLP-1 Agonists Can Affect Mood: A Case of Worsened Depression on Ozempic (Semaglutide). Innov Clin Neurosci. 2024 Jun 1;21(4-6):25-26. PMID: 38938530; PMCID: PMC11208009.
  19. Brierley DI, Holt MK, Singh A, de Araujo A, McDougle M, Vergara M, Afaghani MH, Lee SJ, Scott K, Maske C, Langhans W, Krause E, de Kloet A, Gribble FM, Reimann F, Rinaman L, de Lartigue G, Trapp S. Central and peripheral GLP-1 systems independently suppress eating. Nat Metab. 2021 Feb;3(2):258-273. doi: 10.1038/s42255-021-00344-4. Epub 2021 Feb 15. PMID: 33589843; PMCID: PMC7116821.
  20. Paula-Pérez I. Differential diagnosis between obsessive compulsive disorder and restrictive and repetitive behavioural patterns, activities and interests in autism spectrum disorders. Rev Psiquiatr Salud Ment. 2013 Oct-Dec;6(4):178-86. English, Spanish. doi: 10.1016/j.rpsm.2012.07.005. Epub 2012 Sep 13. PMID: 23084795.
  21. van Steensel FJ, Bögels SM, Perrin S. Anxiety disorders in children and adolescents with autistic spectrum disorders: a meta-analysis. Clin Child Fam Psychol Rev. 2011 Sep;14(3):302-17. doi: 10.1007/s10567-011-0097-0. PMID: 21735077; PMCID: PMC3162631.
  22. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5-TR (5th ed., text rev. ed.). American Psychiatric Association.
    Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). 18 March 2022. doi:10.1176/appi.books.9780890425787
  23. Jiujias M, Kelley E, Hall L. Restricted, Repetitive Behaviors in Autism Spectrum Disorder and Obsessive-Compulsive Disorder: A Comparative Review. Child Psychiatry Hum Dev. 2017 Dec;48(6):944-959. doi: 10.1007/s10578-017-0717-0. PMID: 28281020.
  24. O’Loghlen J, McKenzie M, Lang C, Paynter J. Correction: Repetitive Behaviors in Autism and Obsessive-Compulsive Disorder: A Systematic Review. J Autism Dev Disord. 2024 Aug;54(8):3194-3196. doi: 10.1007/s10803-024-06450-y. Erratum for: J Autism Dev Disord. 2025 Jul;55(7):2307-2321. doi: 10.1007/s10803-024-06357-8. PMID: 38954363; PMCID: PMC11300541.
  25. Sachdeva P, Mehdi I, Kaith R, Ahmad F, Anwar MS. Potential natural products for the management of autism spectrum disorder. Ibrain. 2022 Jun 21;8(3):365-376. doi: 10.1002/ibra.12050. PMID: 37786737; PMCID: PMC10528773.
  26. Herman RJ, Schmidt HD. Targeting GLP-1 receptors to reduce nicotine use disorder: Preclinical and clinical evidence. Physiol Behav. 2024 Jul 1;281:114565. doi: 10.1016/j.physbeh.2024.114565. Epub 2024 Apr 23. PMID: 38663460; PMCID: PMC11128349

Download Article

Received May 17, 2026.
Accepted July 3, 2026.
© 2026 The Author(s). International Journal of Biomedicine is published by IMRDC. This is an open access article under the CC BY-NC-ND 4.0 license.